According to a biomarker analysis from a Phase II trial, cediranib plus olaparib improved progression-free survival versus olaparib in HRR-deficient mCRPC.
San Diego-based Decipher has a portfolio of genomic tests for urologic cancers to improve patient decision-making and accelerate adoption of new therapies.
The first-in-human clinical trial will evaluate XL102 as a treatment for patients with advanced solid tumors, including breast, ovarian, and prostate cancers.
The Japanese Ministry of Health, Labor, and Welfare approved the molecularly defined indications based on data from the PAOLA-1, PROfound, and POLO trials.
The FDA has issued a clinical hold on the company's Phase I/II clinical trial of BPX-601 in patients with advanced pancreatic, gastric, and prostate cancer.
Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.
The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer.
The agency ordered Poseida to halt the trial in August after a patient died but is now allowing the company to resume the study with an amended protocol.
The Prostate Cancer Biomarker Enrichment and Treatment Selection Study will match patients to treatments based on liquid biopsy-based biomarker evaluation.
